Moving Away from Dependence on Existing OEM Arrangements and Launching Products Based on Proprietary New Technologies
First written in FY2023-Q1. 2 of 6 entries say "Restated". Latest entry: 2026-09-03.
0 other companies' latest entry also says "Reframed".
- 2026-09-03ReframedGeneral Meetings of Shareholders
「当社が「PSSプラットフォーム」と称する当社製核酸抽出試薬を使用する遺伝子検査向け装置が堅調に推移したことに加え、過年度からの累計出荷台数増加・蓄積に伴い同装置で使用する核酸抽出試薬及び関連消耗品の売上が大きく伸長しました。」
既存OEM依存からの脱却という従来の表現よりも、PSSプラットフォーム、ODM・自社ブランド装置、専用試薬によるリカーリングモデルを中核とする説明が前面に出た。 - FY2026-H1AdvancedAnnual report
「Overseas sales of ODM products, primarily to major European customers, performed steadily, resulting in net sales of ¥991 million for the six months ended September 30, up 46.5% year on year.」
After setting out the goal of moving away from dependence on existing OEM products and launching new products based on its own technologies, the strategy shifted toward placing the ODM business at its core, and overseas sales of ODM products to major European customers grew materially. - FY2024ReframedAnnual report
「The Company will focus on its core OEM and ODM businesses.」
In contrast to the previous theme of moving away from dependence on existing OEM products, the FY2024 medium- to long-term strategy explicitly shifted toward focusing on the OEM and ODM businesses as core operations. - FY2024-Q1RestatedAnnual report
「Under these circumstances, as a biotechnology venture, our group is pursuing new product development based on the market-launch roadmap, considering new testing businesses, and reforming our business operations.」
The policy of moving away from dependence on existing OEM products and launching new products based on the Company's own technologies has continued in the form of new product development based on the product launch roadmap. - FY2023RestatedAnnual report
「To achieve the medium-term business plan formulated to drive revenue growth and secure profits, the Company has established the following strategic business initiatives: ① expand the product lineup by launching new OEM products and new products based on the Company's own technologies; ② expand testing items by entering into a contract to procure PCR reagents dedicated to fully automated PCR diagnostic instruments; ③ expand domestic and overseas sales networks for the Company's branded products based on its track record of OEM sales worldwide; ④ launch a contract PCR testing business by opening the PSS Shinjuku Laboratory and registering it as a hygiene inspection laboratory; and ⑤ establish a mass-production system for DNA/RNA (nucleic acid) extraction reagent cartridges by establishing a second plant at the PSS Otate Reagent Center.」
The policy of moving away from dependence on existing OEM products and launching new products based on the Company's own technologies was organized and presented again as five strategic themes: product expansion, PCR reagent procurement, sales network expansion, contract testing, and mass production at a second plant. - FY2023-Q1First statedAnnual report
「For the Company, this joint venture is positioned as a business strategy implementing the strategic initiative in the medium-term business plan (FY2023-FY2025) to launch new products based on the Company's own technologies, in order to move away from dependence on existing OEM products.」
The medium-term business plan for the fiscal years ending June 2023 through June 2025 explicitly identified moving away from dependence on existing OEM products and launching new products based on the Company's own technologies as a strategic initiative for the first time.